|
|
 |
|
Viewing report
|
|
|
|
The Future of Systems Biology: Emerging Technologies and their Impact on Drug Discovery, Development and Diagnostics
Business Insights, Sep 2005
'The Future of Systems Biology: Emerging Technologies and their Impact on Drug Discovery, Development and Diagnostics' is a new report which analyzes how systems biology can be used to cut R&D time and costs through improved target identification and lead quality, better elucidation of ADME/Tox profiles, as well as optimizing clinical trial efficiency. This report provides a detailed insight into this complex new process and how it can be used to drive research and development in a variety of biologically-based industries. The competitive landscape of systems biology assessed in this report is supported by case studies of leading companies, enabling you to learn from their experiences and avoid the potential pitfalls. The future of pharmaceuticals lies in combination therapies and more personalized therapeutics. This report will help you to maximize the cost and time saving benefits offered by biological systems in these areas to secure your frontline position in the marketplace.
Key Features:
- Detailed case studies of the pharmaceutical companies using systems biology to improve the drug discovery and development process.
- In-depth profiles on all major companies operating in systems biology, including patent information
- Detailed interviews with three thought leaders in systems biology
- Comprehensive listing of all major international initiatives in systems biology as well as key non-profit research centres
Key Findings
- Reductionist biology, which has been the traditional source of drug discovery, will not supply the solutions to complex diseases such as cancer and diabetes.
- Systems biology can provide the most benefit in improving lead optimization as well as providing better strategies for clinical trials.
- Systems biology offers the opportunity to study targets in an integrated network rather than in isolation.
- Roche uses in silico technologies in approximately 50% of its projects, mostly drugs in Phase II and Phase III clinical trials.
Customers who bought this item also bought
Proteomics - Technologies, Markets and Companies
Biomarkers - Technologies, Markets and Companies
Innovations in Bioinformatics: Emerging Tools for Drug Discovery and Development
Cell Therapy - Technologies, Markets and Companies
Proteomics - Global Strategic Business Report
Enabling Innovation: Drug Development Through Biomarker Validation and Qualification
Nanobiotechnology Applications, Markets and Companies
Cytogenetics - Technologies, Markets and Companies
Biomarkers: Discovery Techniques and Applications – A Global Market Overview
Systems Biology in Biotech and Pharma: A New Paradigm for Innovation
|
|
|
|
